首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

2102961

全球中風治療定價與報銷分析：2026-2035年

Global Stroke Pricing & Reimbursement Analysis, 2026-2035

出版日期: 2026年07月21日 | 出版商:

Knowledge Sourcing Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

醫療保險公司越來越注重成本效益、真實世界的治療結果和健康技術評估 (HTA)，以改善患者獲得醫療保健的機會，同時控制與中風治療相關的日益成長的經濟負擔。

中風是全球主要的死亡和長期殘疾原因之一，造成巨大的直接成本，例如醫療和護理費用，以及間接成本，例如生產力損失。定價和報銷策略在決定患者能否獲得溶栓治療、抗凝血劑、神經保護劑、機械血栓除去裝置、復健服務和新型再生醫學方面起著至關重要的作用。本分析深入探討了主要醫療保健系統中的支付方政策、報銷途徑、醫療技術評估、藥物經濟學評估、定價策略和市場進入機會。

市場促進因素

中風護理醫療費用增加

中風發病率的不斷上升及其導致的長期殘疾負擔，促使世界各國政府和醫療衛生系統加大對急性中風治療、復健和二級預防的投入。這一趨勢也催生了對全面定價和報銷策略日益成長的需求，以支持創新療法的永續普及。

擴展以價值為基礎的醫療保健

醫療保險公司正日益採用基於價值的報銷模式，評估能夠加速功能恢復、減少殘疾、縮短住院時間和降低長期醫療成本的療法。製藥公司也大力投資衛生經濟學和療效研究，以證明新型中風療法的價值。

先進中風治療技術的廣泛應用

機械取栓術、先進神經影像技術、人工智慧診斷和新一代溶栓療法的日益普及正在重塑醫療保險報銷政策。保險公司會根據療效比較、臨床結果和醫療資源的整體活用狀況來評估這些技術。

真實世界證據的重要性日益凸顯

監管機構和報銷機構越來越要求提供長期、真實世界的證據，以證明治療的有效性、安全性、成本降低和生活品質的改善，然後再做出有利的報銷決定。

區域趨勢

北美憑藉其先進的醫療基礎設施、廣泛的保險覆蓋範圍、健全的報銷體係以及創新型卒中治療方法和神經血管器械的快速普及，仍然是卒中治療定價和報銷的最大市場。美國在採用基於價值的支付模式和產生真實世界證據方面繼續發揮主導作用。

歐洲透過集中定價談判、全面的醫療保健技術評估流程以及基於臨床和經濟價值評估治療方案的全民健保系統，保持強大的市場地位。

由於醫療保健支出增加、報銷制度改善、中風治療機會增加以及中國、日本、韓國、印度和澳洲的醫療改革，預計亞太地區將經歷最快的成長。

在拉丁美洲、中東和非洲，透過醫療保健現代化、擴大保險覆蓋範圍以及增加對中風治療基礎設施的投資，正在加強報銷框架。

本報告深入分析了全球中風治療市場，並專注於定價和報銷趨勢。報告內容包括疾病和流行病學分析、市場影響因素、商業化和市場進入趨勢、創新和研發管線趨勢、市場規模趨勢和預測、按不同細分市場和地區分類的詳細分析、相關法規和政策、競爭格局以及主要公司概況。

市場進入概覽
中風治療費用評估
- 急性治療費用
- 住院費
- 復健費用
- 長期照護費用
價格趨勢
- 品牌藥品的價格
- 學名藥的價格
- 生物製藥和專門食品藥物的價格
- 區域價格差異
還款制度分析
- 公共償還
- 私人保險報銷
- 混合還款模式
健康技術評估（HTA）審查
醫療費用支付方的觀點
市場進入障礙
價格比較分析
患者支持和援助計劃
基於價值的合約的發展趨勢
未來還款趨勢

第5章：創新與通路展望

創新概覽
新的治療趨勢
流程概覽：依開發階段分類
- 第一階段
- 第二階段
- 第三階段
管道概覽：依治療方式
- 小分子藥物
- 生物製藥
- 細胞療法
- 基因治療
- 神經保護療法
管線概覽：依作用機轉分類
臨床試驗現狀
授權和合作趨勢
專利情勢分析
未來創新展望

第6章當前治療狀況

治療模式概述
臨床實踐指引審查
急性中風管理
- 靜脈溶栓治療
- 機械血栓切除術
- 抗凝血治療管理
二級預防中風
- 抗血小板治療
- 抗凝血治療
- 降血脂治療
- 血壓管理
復健和恢復管理
治療流程
未滿足的臨床需求

第7章：全球中風治療定價與報銷分析：市場規模與預測

全球市場概覽
過往市場分析
市場預測方法
全球市場收入預測
評估定價的影響
評估還款制度的影響
情境分析

第8章：全球中風治療定價與報銷分析：按細分市場分類

依藥物類型
- 溶栓藥物
- 抗血小板藥物
- 抗凝血劑
- 其他
按類型描邊
- 缺血性中風
- 出血性中風
- 短暫性腦缺血發作（TIA）
- 其他
治療類型
- 靜脈注射藥物
- 血管內治療
- 外科手術
最終用戶
- 醫院
- 專業中風中心
- 復健中心
- 其他

第9章區域分析

北美洲
歐洲
亞太地區
拉丁美洲
中東和非洲
- 市場規模及預測
- 流行病學導論
- 定價環境
- 兌換系統
- 監管概述
- 競爭優勢

第10章：主要國家分析

加拿大
德國
中國
日本
印度

第11章法規與政策概述

世界法規概覽
美國法律規範（FDA）
歐洲法律規範（EMA）
日本法律規範（藥品和醫療設備管理局）
印度的法律規範（CDSCO）
中國的法律規範（NMPA）
價格管制政策
還款政策比較
監管對市場進入的影響
未來政策展望

第12章競爭格局

市佔率分析
競爭性標竿分析
產品系列評估
定價策略分析
贖回策略分析
臨床開發基準測試
策略舉措

第13章：公司簡介

Genentech
Boehringer Ingelheim
F. Hoffmann-La Roche Ltd
Novartis AG
Bayer AG
Johnson & Johnson
Daiichi Sankyo
Sanofi
Novo Nordisk
AstraZeneca PLC
Merck & Co., Inc.
GlaxoSmithKline plc
Eli Lilly and Company
AbbVie Inc.

第14章未來展望

預測期內的市場前景
未來價格趨勢
醫療費用報銷的未來趨勢
新興科技的影響
管道商業化的前景
市場進入的演變
關鍵策略建議
分析師結論

第15章：調查方法

簡介目錄

Product Code: KSI-008958

Healthcare payers are placing greater emphasis on cost-effectiveness, real-world clinical outcomes, and health technology assessment (HTA) to improve patient access while managing the rising economic burden of stroke care.

Stroke is one of the leading causes of mortality and long-term disability worldwide, generating substantial direct and indirect healthcare costs. Pricing and reimbursement strategies play a critical role in determining patient access to thrombolytic therapies, anticoagulants, neuroprotective drugs, mechanical thrombectomy devices, rehabilitation services, and emerging regenerative therapies. Pricing and reimbursement analysis provides valuable insights into payer policies, reimbursement pathways, health technology assessments, pharmacoeconomic evaluations, pricing strategies, and market access opportunities across major healthcare systems.

Market Drivers

Increasing Healthcare Expenditure on Stroke Care

The growing incidence of stroke and the associated long-term disability burden are driving governments and healthcare systems to invest in acute stroke management, rehabilitation, and secondary prevention. This trend is increasing demand for comprehensive pricing and reimbursement strategies that support sustainable access to innovative therapies.

Expansion of Value-Based Healthcare

Healthcare payers are increasingly adopting value-based reimbursement models that reward therapies capable of improving functional recovery, reducing disability, shortening hospital stays, and lowering long-term healthcare costs. Manufacturers are investing heavily in health economics and outcomes research to demonstrate the value of new stroke therapies.

Growing Adoption of Advanced Stroke Technologies

The expanding use of mechanical thrombectomy, advanced neuroimaging, artificial intelligence-assisted diagnosis, and next-generation thrombolytic therapies is reshaping reimbursement policies. Payers are evaluating these technologies based on comparative effectiveness, clinical outcomes, and overall healthcare resource utilization.

Increasing Importance of Real-World Evidence

Regulatory authorities and reimbursement agencies increasingly require long-term real-world evidence demonstrating treatment effectiveness, safety, healthcare savings, and quality-of-life improvements before granting favorable reimbursement decisions.

Market Restraints

High Cost of Innovative Therapies

Advanced stroke therapies, neurovascular devices, and regenerative medicine approaches often carry premium prices, creating reimbursement challenges and limiting patient access in several healthcare systems. Significant disparities remain between high-income and low-income countries in treatment affordability and reimbursement coverage.

Variability in Reimbursement Policies

Pricing and reimbursement frameworks differ considerably across countries because of differences in healthcare financing models, insurance systems, health technology assessment processes, and national budget priorities.

Stringent Health Technology Assessment Requirements

Many reimbursement agencies require comprehensive pharmacoeconomic evidence demonstrating meaningful clinical benefit and cost-effectiveness before approving reimbursement for innovative stroke therapies and medical devices.

Pricing and Reimbursement Insights

The global stroke pricing and reimbursement market can be segmented by therapy type, stroke type, payer type, reimbursement model, end user, and geography.

By therapy type, the market includes thrombolytic therapies, anticoagulants, antiplatelet therapies, neuroprotective therapies, mechanical thrombectomy devices, rehabilitation therapies, and emerging regenerative medicines. Conventional pharmacological therapies continue to receive broad reimbursement, while newer biologics and advanced neurovascular technologies undergo more extensive health technology assessment before reimbursement approval.

By stroke type, reimbursement strategies cover ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke receives the largest reimbursement focus because it represents the majority of stroke cases and the greatest use of high-cost interventions.

By payer type, the market comprises public healthcare systems, private insurance providers, government reimbursement programs, employer-sponsored insurance, and self-pay segments. Public healthcare systems remain the primary source of reimbursement in many countries, while private insurers increasingly adopt value-based payment models.

By reimbursement model, the market includes fee-for-service, bundled payments, diagnosis-related group (DRG) reimbursement, outcome-based agreements, and value-based pricing models. Outcome-based reimbursement is gaining traction as healthcare systems emphasize measurable improvements in patient recovery and long-term cost savings.

By end user, reimbursement covers hospitals, comprehensive stroke centers, specialty neurology clinics, rehabilitation centers, and ambulatory care facilities, with comprehensive stroke centers accounting for the highest utilization of advanced reimbursed therapies.

Pricing and Reimbursement Trends

The stroke pricing and reimbursement landscape continues to evolve alongside healthcare modernization.

Key trends include:

Increasing adoption of value-based reimbursement models.
Greater use of health technology assessments.
Expansion of pharmacoeconomic and budget impact analyses.
Increasing reliance on real-world evidence.
Broader reimbursement for mechanical thrombectomy.
Growing adoption of patient assistance programs.
Earlier integration of market access planning during clinical development.

Regional Insights

North America remains the largest market for stroke pricing and reimbursement because of advanced healthcare infrastructure, extensive insurance coverage, strong reimbursement systems, and rapid adoption of innovative stroke therapies and neurovascular devices. The United States continues to lead implementation of value-based payment models and real-world evidence generation.

Europe maintains a strong position through centralized pricing negotiations, comprehensive health technology assessment processes, and universal healthcare systems that evaluate therapies based on both clinical and economic value.

Asia-Pacific is expected to experience the fastest growth owing to expanding healthcare expenditure, improving reimbursement systems, increasing access to stroke care, and healthcare reforms across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa continue to strengthen reimbursement frameworks through healthcare modernization, broader insurance coverage, and increasing investment in stroke care infrastructure.

Competitive Landscape

The stroke pricing and reimbursement landscape includes pharmaceutical companies, biotechnology firms, neurovascular device manufacturers, health technology assessment agencies, healthcare payers, reimbursement consultants, and market access organizations.

Organizations continue investing in pharmacoeconomic research, health outcomes studies, real-world evidence generation, pricing optimization, and payer engagement strategies. Strategic collaborations, value-based agreements, patient access programs, and evidence-driven reimbursement submissions remain central to successful commercialization.

Future Outlook

The future of stroke pricing and reimbursement will be shaped by wider adoption of value-based healthcare, increasing use of artificial intelligence in health economics, expansion of personalized medicine, and broader integration of real-world evidence into reimbursement decision-making. Outcome-based reimbursement agreements, digital health technologies, and precision medicine are expected to improve patient access while supporting sustainable healthcare spending.

Healthcare systems are also expected to place greater emphasis on early intervention, prevention, rehabilitation, and long-term functional recovery as part of comprehensive reimbursement strategies through 2035.

Conclusion

The global Stroke Pricing & Reimbursement Analysis market is expected to grow steadily through 2035, supported by increasing adoption of advanced stroke therapies, expanding value-based healthcare models, stronger health technology assessment frameworks, and rising investment in real-world evidence. Although premium pricing, reimbursement variability, and regulatory complexity remain important challenges, continued advances in pharmacoeconomic evaluation, market access strategies, and payer engagement are expected to improve reimbursement outcomes and expand patient access to innovative stroke treatments.

Key Benefits of this Report

Comprehensive analysis of global pricing and reimbursement frameworks for stroke therapies and medical devices.
Detailed evaluation of payer strategies, reimbursement pathways, and health technology assessment processes.
Competitive assessment of pricing strategies, pharmacoeconomic trends, and market access developments.
Insights into value-based healthcare, reimbursement innovation, and commercialization opportunities.
Valuable resource for pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Pricing strategy development, reimbursement planning, health technology assessment preparation, market access strategy, pharmacoeconomic evaluation, competitive benchmarking, payer engagement, commercialization planning, investment analysis, and strategic decision-making.

Report Coverage

Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
Comprehensive analysis of global pricing and reimbursement frameworks for stroke therapeutics, neurovascular devices, rehabilitation therapies, and emerging treatment technologies
Assessment of pricing strategies, payer policies, reimbursement models, health technology assessments, pharmacoeconomic evidence, and market access pathways
Evaluation of public and private reimbursement systems, value-based pricing, patient assistance programs, regulatory policies, and regional reimbursement dynamics
Strategic outlook covering future pricing models, reimbursement innovations, health economics, and commercialization opportunities through 2035.

1. Executive Summary

1.1 Report Scope and Objectives
1.2 Stroke Market Overview
1.3 Pricing and Reimbursement Landscape Snapshot
1.4 Key Market Insights
- 1.4.1 Epidemiology Highlights
- 1.4.2 Treatment Access Trends
- 1.4.3 Reimbursement Trends
- 1.4.4 Regulatory Developments
1.5 Key Conclusions and Strategic Recommendations

2. Disease & Epidemiology Analysis

2.1 Stroke Overview
- 2.1.1 Definition and Clinical Classification
- 2.1.2 Disease Burden
- 2.1.3 Risk Factors and Comorbidities
2.2 Stroke Pathophysiology
2.3 Stroke Classification
- 2.3.1 Ischemic Stroke
- 2.3.2 Hemorrhagic Stroke
- 2.3.3 Transient Ischemic Attack (TIA)
2.4 Global Epidemiology Analysis
- 2.4.1 Prevalence
- 2.4.2 Incidence
- 2.4.3 Mortality
- 2.4.4 Disability-Adjusted Life Years (DALYs)
2.5 Epidemiology by Stroke Type
- 2.5.1 Ischemic Stroke Epidemiology
- 2.5.2 Hemorrhagic Stroke Epidemiology
- 2.5.3 TIA Epidemiology
2.6 Epidemiology by Age Group
2.7 Epidemiology by Gender
2.8 Recurrent Stroke Population Analysis
2.9 High-Risk Population Assessment
2.10 Epidemiology Forecast

3. Market Dynamics

3.1 Market Overview
3.2 Market Drivers
- 3.2.1 Increasing Stroke Burden
- 3.2.2 Growing Aging Population
- 3.2.3 Expansion of Acute Stroke Care Infrastructure
- 3.2.4 Increasing Adoption of Secondary Prevention Therapies
- 3.2.5 Expansion of Value-Based Healthcare Models
3.3 Market Restraints
- 3.3.1 High Cost of Stroke Management
- 3.3.2 Reimbursement Variability Across Markets
- 3.3.3 Limited Access to Advanced Therapies
- 3.3.4 Health Technology Assessment Challenges
3.4 Market Opportunities
- 3.4.1 Innovative Reimbursement Models
- 3.4.2 Digital Health Integration
- 3.4.3 Emerging Market Expansion
- 3.4.4 Precision Medicine Opportunities
3.5 Market Challenges
3.6 Porter's Five Forces Analysis
3.7 PESTLE Analysis
3.8 Value Chain Analysis
3.9 Stakeholder Ecosystem Analysis

4. Commercial & Market Access

4.1 Market Access Overview
4.2 Stroke Treatment Cost Assessment
- 4.2.1 Acute Care Costs
- 4.2.2 Hospitalization Costs
- 4.2.3 Rehabilitation Costs
- 4.2.4 Long-Term Care Costs
4.3 Pricing Landscape
- 4.3.1 Branded Drug Pricing
- 4.3.2 Generic Drug Pricing
- 4.3.3 Biologic and Specialty Therapy Pricing
- 4.3.4 Regional Pricing Variations
4.4 Reimbursement Framework Analysis
- 4.4.1 Public Reimbursement
- 4.4.2 Private Reimbursement
- 4.4.3 Hybrid Reimbursement Models
4.5 Health Technology Assessment (HTA) Review
4.6 Payer Perspectives
4.7 Market Access Barriers
4.8 Pricing Benchmarking Analysis
4.9 Patient Assistance and Access Programs
4.10 Value-Based Contracting Trends
4.11 Future Reimbursement Trends

5. Innovation & Pipeline Landscape

5.1 Innovation Overview
5.2 Emerging Therapeutic Trends
5.3 Pipeline Landscape by Development Stage
- 5.3.1 Phase I Assets
- 5.3.2 Phase II Assets
- 5.3.3 Phase III Assets
5.4 Pipeline Landscape by Modality
- 5.4.1 Small Molecules
- 5.4.2 Biologics
- 5.4.3 Cell Therapies
- 5.4.4 Gene Therapies
- 5.4.5 Neuroprotective Therapies
5.5 Pipeline Landscape by Mechanism of Action
5.6 Clinical Trial Landscape
- 5.6.1 Active Trials
- 5.6.2 Recruiting Trials
- 5.6.3 Completed Trials
5.7 Licensing and Collaboration Trends
5.8 Patent Landscape Analysis
5.9 Future Innovation Outlook

6. Treatment Landscape

6.1 Treatment Paradigm Overview
6.2 Clinical Practice Guidelines Review
6.3 Acute Stroke Management
- 6.3.1 Intravenous Thrombolysis
- 6.3.2 Mechanical Thrombectomy
- 6.3.3 Anticoagulation Management
6.4 Secondary Stroke Prevention
- 6.4.1 Antiplatelet Therapy
- 6.4.2 Anticoagulant Therapy
- 6.4.3 Lipid-Lowering Therapy
- 6.4.4 Blood Pressure Management
6.5 Rehabilitation and Recovery Management
6.6 Treatment Algorithms
6.7 Unmet Clinical Needs

7. Global Stroke Pricing & Reimbursement Analysis Size & Forecast

7.1 Global Market Overview
7.2 Historical Market Analysis
7.3 Market Forecast Methodology
7.4 Global Market Revenue Forecast
7.5 Pricing Impact Assessment
7.6 Reimbursement Impact Assessment
7.7 Scenario Analysis
- 7.7.1 Base Case
- 7.7.2 Optimistic Case
- 7.7.3 Conservative Case

8. Global Stroke Pricing & Reimbursement Analysis Segmentation

8.1 By Drug Type
- 8.1.1 Thrombolytics
- 8.1.2 Antiplatelet Agents
- 8.1.3 Anticoagulants
- 8.1.4 Others
8.2 By Stroke Type
- 8.2.1 Ischemic Stroke
  - 8.2.1.1. Thrombotic
  - 8.2.1.2. Embolic
- 8.2.2 Hemorrhagic Stroke
- 8.2.3 Transient Ischemic Attack
- 8.2.4 Others
8.3 By Treatment Type
- 8.3.1 IV Medication
- 8.3.2 Endovascular Therapy
- 8.3.3 Surgical Procedures
  - 8.3.3.1 Mechanical Thrombectomy
  - 8.3.3.2 Carotid Endarterectomy (CEA)
  - 8.3.3.3 Others
8.4 By End User
- 8.4.1 Hospitals
- 8.4.2 Specialty Stroke Centers
- 8.4.3 Rehabilitation Centers
- 8.4.4. Others

9. Geographical Analysis

9.1 North America
- 9.1.1 Market Size and Forecast
- 9.1.2 Epidemiology Overview
- 9.1.3 Pricing Environment
- 9.1.4 Reimbursement Framework
- 9.1.5 Regulatory Overview
- 9.1.6 Competitive Intensity
9.2 Europe
- 9.2.1 Market Size and Forecast
- 9.2.2 Epidemiology Overview
- 9.2.3 Pricing Environment
- 9.2.4 Reimbursement Framework
- 9.2.5 Regulatory Overview
- 9.2.6 Competitive Intensity
9.3 Asia-Pacific
- 9.3.1 Market Size and Forecast
- 9.3.2 Epidemiology Overview
- 9.3.3 Pricing Environment
- 9.3.4 Reimbursement Framework
- 9.3.5 Regulatory Overview
- 9.3.6 Competitive Intensity
9.4 Latin America
- 9.4.1 Market Size and Forecast
- 9.4.2 Epidemiology Overview
- 9.4.3 Pricing Environment
- 9.4.4 Reimbursement Framework
- 9.4.5 Regulatory Overview
- 9.4.6 Competitive Intensity
9.5 Middle East & Africa
- 9.5.1 Market Size and Forecast
- 9.5.2 Epidemiology Overview
- 9.5.3 Pricing Environment
- 9.5.4 Reimbursement Framework
- 9.5.5 Regulatory Overview
- 9.5.6 Competitive Intensity

10. Key Countries Analysis

10.1 United States
- 10.1.1 Market Size
- 10.1.2 Epidemiology
- 10.1.3 Regulatory Framework
- 10.1.4 Reimbursement Landscape
- 10.1.5 Key Companies and Product Presence
10.2 Canada
- 10.2.1 Market Size
- 10.2.2 Epidemiology
- 10.2.3 Regulatory Framework
- 10.2.4 Reimbursement Landscape
- 10.2.5 Key Companies and Product Presence
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
10.9 Japan
10.10 India
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa

11. Regulatory & Policy Landscape

11.1 Global Regulatory Overview
11.2 United States Regulatory Framework (FDA)
- 11.2.1 Drug Approval Pathways
- 11.2.2 Market Access Requirements
- 11.2.3 Reimbursement Policy Environment
11.3 Europe Regulatory Framework (EMA)
- 11.3.1 Centralized Approval Procedures
- 11.3.2 Market Access Requirements
- 11.3.3 HTA Integration
11.4 Japan Regulatory Framework (PMDA)
11.5 India Regulatory Framework (CDSCO)
11.6 China Regulatory Framework (NMPA)
11.7 Pricing Control Policies
11.8 Reimbursement Policy Comparison
11.9 Regulatory Impact on Market Access
11.10 Future Policy Outlook

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Product Portfolio Assessment
12.4 Pricing Strategy Analysis
12.5 Reimbursement Strategy Analysis
12.6 Clinical Development Benchmarking
12.7 Strategic Initiatives
- 12.7.1 Partnerships
- 12.7.2 Licensing Agreements
- 12.7.3 Acquisitions
- 12.7.4 Collaborations

13. Company Profiles

13.1 Genentech
- 13.1.1 Company Overview
- 13.1.2 Approved Products Relevant to Stroke Care
- 13.1.3 Key Indications
- 13.1.4 Verified Clinical Pipeline
- 13.1.5 Pricing and Market Access Strategy
- 13.1.6 SWOT Analysis
13.2 Boehringer Ingelheim
- 13.2.1 Company Overview
- 13.2.2 Approved Products Relevant to Stroke Care
- 13.2.3 Key Indications
- 13.2.4 Verified Clinical Pipeline
- 13.2.5 Pricing and Market Access Strategy
- 13.2.6 SWOT Analysis
13.3 F. Hoffmann-La Roche Ltd
13.4 Novartis AG
13.5 Bayer AG
13.6 Johnson & Johnson
13.7 Daiichi Sankyo
13.8 Sanofi
13.9 Novo Nordisk
13.10 AstraZeneca PLC
13.11 Merck & Co., Inc.
13.12 GlaxoSmithKline plc
13.13 Eli Lilly and Company
13.14 AbbVie Inc.